Cart
sales@molnova.com
Home - Products - Apoptosis - TNF - Utomilumab

Utomilumab

CAS No. 1417318-27-4

Utomilumab( —— )

Catalog No. M36677 CAS No. 1417318-27-4

Utomilumab (PF 05082566) is a humanized IgG2 antibody that targets the T-cell co-stimulatory receptor 4-1BB/CD137 and acts as a 4-1BB/CD137 agonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 451 Get Quote
5MG 710 Get Quote
10MG 1121 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Utomilumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Utomilumab (PF 05082566) is a humanized IgG2 antibody that targets the T-cell co-stimulatory receptor 4-1BB/CD137 and acts as a 4-1BB/CD137 agonist.
  • Description
    Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20+ non-Hodgkin lymphomas (NHL).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    TNF
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1417318-27-4
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Anthony W Tolcher, et al. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Sep 15;23(18):5349-5357.?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • XYLOBIOSE

    XYLOBIOSE ia a natural productand exhibited therapeutic potential for treating obesity which involved suppression of fat deposition and obesity-related metabolic disorders.

  • UTL-5g

    UTL-5g is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity.

  • Adalimumab

    Adalimumab anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

Sign In Join Free